Clinical Trial Detail

NCT ID NCT02513394
Title PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Alliance Foundation Trials, LLC.
Indications

Her2-receptor negative breast cancer

Therapies

Palbociclib

Age Groups: adult senior

Additional content available in CKB BOOST